AbCellera Results Presentation Deck

FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 $316.5M total revenue, driven by royalties for bamlanivimab and bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $202.8M $171.5M $7.0M $4.0M Q1 2021 $20.3M $316.5M $307.0M $9.3M $0.2M Q1 2022

View entire presentation